Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 38Colorectal Neoplasms 18Stomach Neoplasms 7Biliary Tract Neoplasms 5Rectal Neoplasms 3Neoplasm Metastasis 3Cholangiocarcinoma 3Neoplasms 2Metastatic Pancreatic Adenocarcinoma 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Wilms Tumor 1Weight Loss 1Triple Negative Breast Neoplasms 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Cancer Patients 1Pseudomyxoma Peritonei 1Peritoneal Neoplasms 1Pancreatic cancer, adult 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic to Liver 1Pancreatic Adenocarcinoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1

Interventions

camrelizumab 2apatinib 2Ramucirumab 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × irinotecan sucrosofate × Gastrointestinal × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡